EGI
RAPT

EAM Global Investors’s RAPT Therapeutics RAPT Stock Holding History

EAM Global Investors’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,910
Closed -$1.76M – 232
2021
Q2 		$1.76M Buy
+6,910
New +$1.29M 0.49% 124

Other funds holding RAPT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM Global Investors's RAPT Position: Q3 2021 in Review

EAM Global Investors sold out of RAPT Therapeutics (RAPT) in Q3 2021, closing a stake of 6,910 shares — an estimated $1.76M sold.

EAM Global Investors first reported a position in RAPT in Q2 2021 and held it in 1 quarter. The position peaked at $1.76M in Q2 2021. 106 funds tracked by Wall St. Rank hold RAPT as of Q3 2021.

  • EAM Global Investors reported no remaining RAPT Therapeutics position as of Q3 2021 after selling out during the quarter.
  • EAM Global Investors sold 6,910 RAPT Therapeutics shares in Q3 2021, an estimated $1.76M.
  • EAM Global Investors first reported a position in RAPT Therapeutics in Q2 2021 and held it in 1 quarter.
  • EAM Global Investors's RAPT Therapeutics position peaked at $1.76M in Q2 2021.
  • 106 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2021.

Based on EAM Global Investors's 13F filing for Q3 2021, filed 12 Nov 2021.